Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D01CYT
|
|||
| Former ID |
DIB004044
|
|||
| Drug Name |
ELND-002
|
|||
| Synonyms |
ELND-002 (oral, multiple sclerosis); Alpha-4 integrin antagonists (oral, autoimmune diseases), Elan; Alpha-4 integrin antagonists (oral, multiple sclerosis), Elan; ELND-002 (oral, multiple sclerosis), Elan
Click to Show/Hide
|
|||
| Indication | Autoimmune diabetes [ICD-11: 5A10] | Phase 1 | [1] | |
| Company |
Elan Corp plc
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01318421) A Study of ELND002 in Patients With Relapsing Forms of Multiple Sclerosis. U.S. National Institutes of Health. | |||
| REF 2 | Paxillin binding to the alpha 4 integrin subunit stimulates LFA-1 (integrin alpha L beta 2)-dependent T cell migration by augmenting the activation of focal adhesion kinase/proline-rich tyrosine kinase-2. J Immunol. 2003 Jun 15;170(12):5912-8. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.